Articles related to IMMUNOTHERAPY

An in-depth look at the FDA’s clinical hold on Iovance’s lung cancer cell therapy trial reveals crucial insights into the safety and progression of innovative cancer treatments.

The bispecific antibody targets both CD20 and CD3 proteins and has demonstrated the capacity of activated immune cells to eliminate lymphoma cells, achieving deep and potentially curable remissions.

This recent study suggests that systemic treatment with chemotherapy plus immunotherapy may allow patients with muscle-invasive bladder cancer (MIBC) to avoid radical cystectomy.

This phase 2 trial demonstrated that tarlatamab showed antitumor activity with durable objective responses and promising survival outcomes in patients with previously treated small-cell lung cancer. With a manageable safety profile and no new safety signals identified, tarlatamab could represent a significant advancement in the treatment landscape for these patients.

Discover how CRISPR-engineered CD45 CAR T-cells could alter the treatment landscape for various blood cancers, offering a more versatile and less risky approach.

Discover how base editing via CRISPR-guided cytidine deamination could revolutionize CAR T-cell therapy for T-cell cancers, offering a promising approach to treating relapsed or refractory cases in pediatric patients.